In September 2019, the Bill & Melinda Gates Foundation announced a $55 million equity investment in BioNTech. BioNTech’s stock was trading between $15 and $20 following its IPO in October 2019.

In 2020, BioNTech partnered with Pfizer to develop the BNT162b2 vaccine. It became the first COVID-19 mRNA vaccine to receive emergency use authorization (EUA) in the UK (December 2) and the US (December 11, 2020).

It did not take long for BioNTech’s stock ($BNTX) to experience massive growth during the pandemic. It reached an all-time high of approximately $440 per share in August 2021, though it fluctuated and averaged near the $350–$400 range during its peak months.

In early April 2026, Pfizer and BioNTech officially halted a large-scale U.S. clinical trial involving healthy adults aged 50–64.

The companies cited “slow enrollment” as the primary reason, stating they could not gather enough participants to meet the FDA’s data requirements for expanded vaccine recommendations.

To receive free email notification, when we post new articles like this, sign up below. Clever Journeys does & will not sell or share your information with anyone.

☆☆☆☆☆

IN GOD WE TRUST

Thanks for supporting independent true journalism with a small tip. Dodie & Jack

10% Discount Today on Green Pasture Health Products